Compass Pathways reported a second pivotal phase 3 success for its psilocybin therapy in treatment-resistant depression, boosting its shares roughly 30% and setting up plans to seek regulatory approval.
Longevity News
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sendi...
Source: FierceBiotech - Biotech • Published: 20 Feb 2026, 11:32
Continue exploring
Related longevity signals
Nature - BiotechnologyOral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trialReports a multicenter phase II trial testing an oral nonpeptide GLP-1 receptor agonist for obesity, its dosing options, and short-term efficacy and tolerability.Longevity TechnologyAltimmune starts Phase 3 testing for fatty liver treatmentA biotech update on the start of late-stage clinical testing for a metabolic liver therapy, previewing trial aims and development context.Frontiers - HealthAcute otitis media complicated by mastoiditis and otogenic transverse-sigmoid sinus thrombosis in an adult: a case report on infectious pathogenesis and multidisciplinary therapyA clinical case describing adult acute otitis media that progressed to mastoiditis with sigmoid plate erosion and transverse-sigmoid sinus thrombosis, and multidisciplinary management.Longevity TechnologyXellSmart scores FDA fast track for Parkinson’s cell therapyNews about regulatory momentum for an off-the-shelf cell therapy for Parkinson’s, previewing a piece on its clinical and manufacturing implications.